Fulcrum Therapeutics to Present at Investor Conferences with Pociredir Data

Fulcrum Therapeutics, a biopharmaceutical company, will present at two upcoming investor conferences. The company's management team will attend the Cantor Fitzgerald 2025 Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Fulcrum's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease.

Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will present at two upcoming investor conferences. The company's management team will attend the Cantor Fitzgerald 2025 Annual Global Healthcare Conference in New York, NY, on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY, on September 9, 2025 [1].

The company's lead clinical program, pociredir, is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in HbF. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD [1].

Fulcrum Therapeutics has received a consensus recommendation of "Moderate Buy" from eight research firms, indicating mixed confidence in its stock performance. Analysts have set an average 1-year price target of $7.57, with price targets ranging from $5.00 to $12.00 based on various ratings from multiple brokerages [2].

The company's stock traded down $0.47 during midday trading on Friday, hitting $6.41. The firm has a market capitalization of $346.72 million, a PE ratio of -5.25 and a beta of 2.47. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $9.90. The business has a fifty day simple moving average of $7.11 and a two-hundred day simple moving average of $5.29 [2].

References:
[1] https://www.marketscreener.com/news/fulcrum-therapeutics-to-present-at-upcoming-investor-meetings-ce7c50d9db89f52d
[2] https://www.marketbeat.com/instant-alerts/fulcrum-therapeutics-inc-nasdaqfulc-receives-average-recommendation-of-moderate-buy-from-brokerages-2025-08-22/